The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Open accessAbstract
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19- leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Further, transduction of cells other than T lymphocytes (e.g. malignant blasts) has been observed, creating the risk of engineering CARs into cancer cells, giving rise to CAR-resistant tumor cells (48).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationSöker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,493
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Self-citationChimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citation
Research works printed but not linked: 1
- Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J. & Pastan, I. Clin. Cancer Res. 8, 995–1002 (2002).
Cited by
Sorted by citations
Items 601–659 of 659
Wadhwa, A., Johnson, H. E., Bobba, K. N., Bidkar, A. P., Mayne, E., Rampersaud, S., Mandal, K., Barpanda, A., Prudhvi, S., Kang, A. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.21.671206
徐, 慧. (2025) · Pharmacy Information · doi:10.12677/pi.2025.145037
SOHO State of the Art Updates and Next Questions | The Promise of Immunotherapies in T-Cell Lymphoma
Thomas, C. J., & Barta, S. K. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.09.006
Development and function of γδ T cells
Bychkov, I., & Wiest, D. L. (2025) · International review of cytology · doi:10.1016/bs.ircmb.2025.08.012 · Cited by 1
Roura, C. D., Amrolia, P. J., Ansari, M., Bader, P., Balduzzi, A., Buechner, J., Hsieh, E. M., Myers, R. M., Ottaviano, G., Peters, C., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.10.023
ATF6 and pS6K as prognostic biomarkers in newly diagnosed diffuse large B-cell lymphoma
Su, S., Wu, L., Huang, C., Wang, L., Li, W., Liu, W., & Liu, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-22920-4
Li, H., Wang, Y., Liu, R., Li, X., Zhang, P., Chen, P., Zhao, N., Li, B., Wang, J., & Tang, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25876343
Li, H., Wang, Y., Liu, R., Li, X., Zhang, P., Chen, P., Zhao, N., Li, B., Wang, J., & Tang, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26723918
Li, H., Wang, Y., Liu, R., Li, X., Zhang, P., Chen, P., Zhao, N., Li, B., Wang, J., & Tang, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26723924
Zhang, Y., Patel, R. P., Kim, K. H., Cho, H., Jo, J.-C., Jeong, S. H., Oh, S. Y., Choi, Y. S., Kim, S. H., Lee, J. H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26651538
Self-citationLi, H., Wang, Y., Liu, R., Li, X., Zhang, P., Chen, P., Zhao, N., Li, B., Wang, J., & 汤永民 (2024) · Figshare · doi:10.6084/m9.figshare.25876174
Additional file 2 of The journey of CAR-T therapy in hematological malignancies
Lu, J., & Jiang, G. (2022) · Figshare · doi:10.6084/m9.figshare.21303550
Additional file 1 of In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma
Krug, A., Saidane, A., Martinello, C., Fusil, F., Michels, A., Buchholz, C. J., Ricci, J., & Verhoeyen, E. (2024) · Figshare · doi:10.6084/m9.figshare.27019260
Li, H., Wang, Y., Liu, R., Li, X., Zhang, P., Chen, P., Zhao, N., Li, B., Wang, J., & 汤永民 (2024) · Figshare · doi:10.6084/m9.figshare.26723921
Chen, Y.-J., Chen, M. J., Cheng, T.-L., Tsai, Y.-S., Wang, C.-H., Chen, C.-Y., Wu, T.-Y., Tzou, S.-C., Wang, K.-H., Cheng, J.-J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26593136
Zhang, Y., Patel, R. P., Kim, K. H., Cho, H., Jo, J.-C., Jeong, S. H., Oh, S. Y., Choi, Y. S., Kim, S. H., Lee, J. H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26651541
Self-citationAdditional file 1 of The journey of CAR-T therapy in hematological malignancies
Lu, J., & Jiang, G. (2022) · Figshare · doi:10.6084/m9.figshare.21303547
Modular construction of bispecific antibodies through bioconjugation for T cell-based immunotherapyPreprint
Sun, S.-Q., Wang, L., Xia, J., Li, S., Zhu, J.-M., Cai-wen, D., & Chen, K. (2026) · Research Square · doi:10.21203/rs.3.rs-8371642/v1
Li, F., & Zheng, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1691189
Ferrari, D. I., Alvarez, I. K., Zhang, M. L., Wilson, L., & Ramirez, R. Y. (2024) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/7dhofgll67
Liu, X., Gao, H., & Yu, J. (2026) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbag007
Lecornec, N., Rabian, F., Dourthe, M.-É., Chevillon, F., Yakouben, K., Chaillou, D., Caillat‐Zucman, S., Cuffel, A., Lesprit, E., Arnould, A., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02867-9
Gene therapy breakthroughs in leukemia treatment and future prospects
Sowmiya, S., Begum, R. F., Nirenjen, S., Singh, A., Harikrishnan, N., Prajapati, B. G., & Ankul Singh, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44000-7.00008-5
A gene-editing method generates immunotherapeutic CAR T cells in the body
Holt, R. A., & Evgin, L. (2026) · Nature · doi:10.1038/d41586-026-00634-5
Review Article: Overcoming Antigen Expression Barriers in CAR-T Therapy for Solid Tumors
Moon, O. R., Bridgeman, J. S., & 包乐媛 (2026) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2026064031
Engineering precision oncology: Targeting tumors and immune cells with lentiviral vectors
Rossi, J., Martinello, C., Sorrentino, R. G., Guyonnet‐Dupérat, V., Amintas, S., Abrey-Recalde, M. J., Verhoeyen, E., & Dabernat, S. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201197
HVEM : une nouvelle cible prometteuse d'immunothérapie anti-cancéreuse
Demerle, C. (2023) · theses.fr (ABES) · doi:10.70675/9e290f7fz176bz4249zba2aze5e67eeff324
Les translocations chromosomiques : des modifications cellulaires à l'oncogenèse
Darchen, A. (2023) · theses.fr (ABES) · doi:10.70675/46502e8dz57a3z448cz9cfazd2757610dcf4
Li, B., Wen, R., Hong, K., Wu, F., Mao, J., Zhou, X., Xie, H., Qiu, X., Azad, T., Tian, J., et al. (2026) · International Reviews of Immunology · doi:10.1080/08830185.2026.2669734
Challenges and advances in CAR-T cell therapy for B-ALL
Zha, C., & Wang, Y. (2026) · Biomarker Research · doi:10.1186/s40364-026-00933-z
Samsonov, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.15.725377
TRAC in vivo: culmination of CAR and vector engineering
Cabriolu, A., & Sadelain, M. (2026) · Cell Research · doi:10.1038/s41422-026-01255-3
Manufacturing as biology: How T-cell processing shapes therapeutic outcomes
Przybylski, N., Zeng, Q., & Huang, X. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.05.005
Daneshvar, A., Mashayekhi, R., & Sharifnia, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.24.727464
Li, P., Xue, X., & Zhang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1861111
Ke, Q.-H., & Zhou, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1856798
Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid TumorsPreprint
Alam, R., Kumar, S., Shukla, R., Chaudhary, N., Gupta, J., Sinha, A., Chaudhuri, R., Ranganathan, M., Husain, K., Shaikh, N. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.30.735484
Chen, R., Zheng, H., Wang, W. L., Fu, S., Zhang, M., Feng, J., Chang, A. H., Ren, J., Pei, S., Huang, H., et al. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0489
Yoziyeva, U., Yumashev, A., Shokirovna, K. S., Khaydarova, D. K., Umurzoqovna, N. D., Axmedova, N., Ishanovna, S. M., & Khudoykulova, Z. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.07.003
Rewiring cellular immunotherapy: From CAR evolution to circuit innovations across diseases
Chen, J., Cui, Y., Du, K., Liu, J., Xie, J., Wang, S., & Yang, Z. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108980
Li, W. (2026) · Springer eBooks · doi:10.1007/978-3-032-26557-9_16
Qin, X., Hou, S., Sun, Z., Xu, G., Huo, Y., Luo, Y., Liang, C., & Wang, J. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100012
Resistance to CAR-based cell therapy: Mechanisms and overcoming strategies
Sha, S., Pang, X.-Y., Wang, N., Wang, Y., Zhang, C., Guo, Z., Du, Z., Li, L., Liu, N., & Qu, L. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101452
The eco-evolutionary dynamics of acute myeloid leukemia: From clonal games to clinical intervention
Ye, C., Fu, S., Li, J., Xue, J., & Li, J. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101349
Ultrasound controllable and antigen-independent killing via cis-activating CAR T cells
Zhu, L., Cui, J., Man, C., Mouchawar, A. C., Yu, X., Huang, Y., Wu, Y., Guo, T., Xu, H., Liu, L., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201323
Universal CAR-T cell therapy: mechanisms and evasion strategies of bidirectional immune rejection
Ding, L., Zhao, L., Zhang, M., Chen, T., & Guo, Z. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189690
In vivo CAR‑T therapy: recent progress and future directions
Wang, W., Cai, Y., Yang, X., & Xu, H. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00050-4
CAR T-Cell Therapy in Acute Lymphoblastic Leukemia—Is Limited Persistence Enough?
Lucchini, G., Ottaviano, G., & Biondi, A. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.3016
In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers
Huo, T., Yao, H., & Kong, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1927594
Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid TumorsPreprint
Ahmad, T., Alam, R., Divya, Sharma, S., Kumar, S., Gupta, J., Chauhan, V., Uddin, I. M., Shakir, M., Ansari, M. A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10839023/v1
Kovács, Z., Szabo, K., Nagy, G., & Toth, E. (2026) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/ldylrro6ln
Therapeutic Cancer Vaccines: Classification, Mechanisms, Challenges and Future Perspectives
Gao, J., Sun, Y., Han, Z., Zhang, H., Sun, M., Liu, S., & Zhang, B. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2733761
CAR-T in vivo : quand le patient devient sa propre usine de production
Vilcot, F., Brugère, C.-A., Fuentealba, J., & Houot, R. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2026.07.016
Xu, J., Sui, L., Yang, W., Xu, L., & Shan, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1909384
Self-citationToward the next generation of CAR T cell therapies for cancer
Usta, D., & Mackall, C. L. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.005
Irimia, R. M., & Piccaluga, P. P. (2026) · Cancers · doi:10.3390/cancers18203400
The summa of ZUMA: Lessons from a decade of CD19-targeted CAR-T trials in B-cell malignancies
Hincapie, J. S. V., Mondragon-Cardona, A., Ochoa-Zárate, L., Cabrera-Salcedo, S. C., Ríos-Serna, L. J., Loukanov, A. R., García-Robledo, J. E., Toro-Pedroza, A., Cañas, C. A., Arrieta, E., et al. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108356
Metadata
- Authors
- Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., Nazimuddin, F., Bhoj, V. G., Orlando, E. J., Fry, T. J., Bitter, H., Maude, S. L., Levine, B. L., Nobles, C. L., Bushman, F. D., Young, R. M., Scholler, J., Gill, S. I., June, C. H., Grupp, S. A., Lacey, S. F., & Melenhorst, J. J.
- Affiliations
- Abramson Cancer Center (US)
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
- Children's Hospital Colorado (US)
- Corresponding author
- June, Carl H.
- Melenhorst, J. Joseph
- ORCID
- Ruella, Marco
- Xu, Jun
- Barrett, David M.
- Fraietta, Joseph A.
- Reich, Tyler J.
- Klichinsky, Michael
- Patel, Prachi R.
- Kulikovskaya, Irina
- Bhoj, Vijay G.
- Orlando, Elena J.
- Fry, Terry J.
- Bitter, Hans
- Maude, Shannon L.
- Levine, Bruce L.
- Nobles, Christopher L.
- Bushman, Frederic D.
- Young, Regina M.
- Scholler, John
- Gill, Saar I.
- June, Carl H.
- Grupp, Stephan A.
- Lacey, Simon F.
- Melenhorst, J. Joseph
- Venue
- Nature Medicine
- Published
- 2018-10
- Volume
- 24
- Issue
- 10
- Pages
- 1499-1503
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC6511988
- OpenAlex
- W2893691711
- Cited by
- 659
- References
- 36
- Citations by year
- 2026: 61 · 2025: 73 · 2024: 83 · 2023: 84 · 2022: 83 · 2021: 91 · 2020: 91 · 2019: 78 · 2018: 14
- FWCI
- 25.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K99CA212302, R00CA212302, T32CA009140, R01CA120409, P01CA214278)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- CAR T-cell therapy, CD19, tisagenlecleucel, B-cell acute lymphoblastic leukemia, CAR T cell manufacturing, relapse
- MeSH terms
- Receptors, Chimeric Antigen, Adult, Epitopes, B-Lymphocytes, Humans, Leukemia, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Antigens, CD19, Drug Resistance, Neoplasm, Young Adult, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
